Markets Stocks Economy Crypto Earnings Banking Energy
Home Stocks Feature
Stocks · Exclusive

Back-to-school sales surge 9.6%, but discretionary stocks slip

Back-to-school sales surge 9.6%, but discretionary stocks slip
Stocks · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Sep 1, 2026 3 min read

Back-to-school shopping appears to be off to a strong start, according to the latest Redbook data. The high-frequency tracker of U.S. chain-store revenue reported that same-store sales rose 9.6% year over year in the week ended Aug. 29, up from 9.1% the week before. Retailers cited solid demand for kids' apparel and footwear, a positive sign for the crucial back-to-school season.

Yet the market's reaction on Tuesday told a more nuanced story. Consumer staples stocks rose 0.6%, while consumer discretionary stocks fell 1.6%. That divergence suggests investors are not fully convinced that strong sales will translate into stronger profits.

Why strong sales don't always mean strong profits

Redbook's same-store sales measure tracks revenue at chain stores open at least a year. It's a widely watched gauge of consumer spending, especially during seasonal peaks like back-to-school. A 9.6% jump is a healthy increase, indicating that households are still opening their wallets despite lingering inflation and higher interest rates.

But revenue is only half the story. If shoppers are gravitating toward lower-margin items, or if retailers are leaning on discounts to move inventory, earnings can lag even when sales look robust. That's a key reason why discretionary stocks—which include retailers, apparel makers, and other non-essential goods—might slip even on good sales news. Investors are likely weighing whether the sales surge is sustainable and whether it will actually boost bottom lines.

Consumer staples, by contrast, tend to be more defensive. They sell everyday necessities like food, household products, and personal care items, which are less sensitive to economic swings. When investors feel uncertain about the consumer or the broader economy, they often rotate into staples as a safer bet. Tuesday's 0.6% gain in staples, alongside the 1.6% drop in discretionary, fits that pattern.

What this means for investors

For everyday investors, the takeaway is that strong economic data doesn't always move markets in a straight line. The Redbook report is a snapshot of consumer activity, but stock prices reflect expectations about future profits, not just current sales. If retailers are sacrificing margins to drive volume, the market may punish those stocks even as headlines tout strong demand.

This is especially relevant in a period when rate-hike bets are rising, which can pressure consumer spending and corporate borrowing costs. Higher interest rates make it more expensive for shoppers to finance big purchases and for companies to fund inventory. That backdrop could explain why investors are cautious about discretionary names despite the upbeat sales data.

It's also worth noting that back-to-school is a bellwether for the holiday season. If this strength continues, it could bode well for retailers later in the year. But if the sales surge is driven by heavy discounting, the holiday quarter might not deliver the profit growth investors hope for.

Looking ahead

Investors will be watching upcoming earnings reports from major retailers to see whether sales growth is translating into earnings growth. They'll also keep an eye on consumer confidence and inflation data, which can influence spending patterns. The Redbook numbers are just one piece of the puzzle, but they offer an early read on the consumer's health.

For now, the split between staples and discretionary stocks suggests a market that's cautious about the consumer's ability to keep spending at this pace. As always, it's important to focus on the fundamentals of individual companies rather than reacting to a single data point. Strong sales are good, but profitable sales are better.

More from this story

Next article · Don't miss

Chip and pharma projects could lift US factory construction above $200B

UBS expects US factory construction to rebound, led by new chip and pharma projects. Manufacturing-related building could top $200 billion by end of next year after a recent slowdown.

Read the story →
Chip and pharma projects could lift US factory construction above $200B